BR112018073553A2 - medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. - Google Patents
medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.Info
- Publication number
- BR112018073553A2 BR112018073553A2 BR112018073553-1A BR112018073553A BR112018073553A2 BR 112018073553 A2 BR112018073553 A2 BR 112018073553A2 BR 112018073553 A BR112018073553 A BR 112018073553A BR 112018073553 A2 BR112018073553 A2 BR 112018073553A2
- Authority
- BR
- Brazil
- Prior art keywords
- fibromyalgia
- symptoms associated
- pharmaceutical composition
- functional symptoms
- preventing
- Prior art date
Links
- 208000001640 Fibromyalgia Diseases 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- -1 carbamate compound Chemical class 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160061392 | 2016-05-19 | ||
| KR10-2016-0061392 | 2016-05-19 | ||
| PCT/KR2017/005173 WO2017200318A1 (ko) | 2016-05-19 | 2017-05-18 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018073553A2 true BR112018073553A2 (pt) | 2019-03-19 |
Family
ID=60325216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018073553-1A BR112018073553A2 (pt) | 2016-05-19 | 2017-05-18 | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10849882B2 (enExample) |
| EP (1) | EP3459543B1 (enExample) |
| JP (1) | JP7071287B2 (enExample) |
| KR (1) | KR102489052B1 (enExample) |
| CN (1) | CN109475529B (enExample) |
| AU (1) | AU2017265839B2 (enExample) |
| BR (1) | BR112018073553A2 (enExample) |
| DK (1) | DK3459543T3 (enExample) |
| ES (1) | ES2935596T3 (enExample) |
| MX (1) | MX394245B (enExample) |
| PL (1) | PL3459543T3 (enExample) |
| RU (1) | RU2753525C2 (enExample) |
| WO (1) | WO2017200318A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102635941B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| EP3711757B1 (en) * | 2017-11-14 | 2025-05-07 | SK Biopharmaceuticals Co., Ltd. | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| ES2973111T3 (es) * | 2017-11-14 | 2024-06-18 | Sk Biopharmaceuticals Co Ltd | Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio |
| CN111432812A (zh) | 2017-11-14 | 2020-07-17 | 爱思开生物制药株式会社 | 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途 |
| KR20210062029A (ko) | 2018-10-19 | 2021-05-28 | 에스케이바이오팜 주식회사 | 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도 |
| AU2020389425B2 (en) * | 2019-11-22 | 2026-03-05 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
| IT202300007314A1 (it) | 2023-04-14 | 2024-10-14 | Soal Pharma Srl | Integratore alimentare per il trattamento della fibromialgia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| RU2299729C2 (ru) * | 2001-07-16 | 2007-05-27 | Орто-Макнейл Фармасьютикал, Инк. | Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| AU2009348523B2 (en) * | 2009-06-22 | 2015-02-26 | Sk Biopharmaceuticals Co., Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| EP2496227B1 (en) * | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
-
2017
- 2017-05-16 KR KR1020170060714A patent/KR102489052B1/ko active Active
- 2017-05-18 PL PL17799675.8T patent/PL3459543T3/pl unknown
- 2017-05-18 EP EP17799675.8A patent/EP3459543B1/en active Active
- 2017-05-18 DK DK17799675.8T patent/DK3459543T3/da active
- 2017-05-18 WO PCT/KR2017/005173 patent/WO2017200318A1/ko not_active Ceased
- 2017-05-18 US US16/302,858 patent/US10849882B2/en active Active
- 2017-05-18 CN CN201780030906.XA patent/CN109475529B/zh active Active
- 2017-05-18 AU AU2017265839A patent/AU2017265839B2/en active Active
- 2017-05-18 MX MX2018014080A patent/MX394245B/es unknown
- 2017-05-18 ES ES17799675T patent/ES2935596T3/es active Active
- 2017-05-18 RU RU2018144785A patent/RU2753525C2/ru active
- 2017-05-18 BR BR112018073553-1A patent/BR112018073553A2/pt not_active Application Discontinuation
- 2017-05-18 JP JP2018560460A patent/JP7071287B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2935596T3 (es) | 2023-03-08 |
| PL3459543T3 (pl) | 2023-04-11 |
| EP3459543B1 (en) | 2022-12-21 |
| US20190298694A1 (en) | 2019-10-03 |
| MX394245B (es) | 2025-03-19 |
| CN109475529A (zh) | 2019-03-15 |
| RU2018144785A (ru) | 2020-06-19 |
| EP3459543A4 (en) | 2020-01-15 |
| KR102489052B1 (ko) | 2023-01-16 |
| DK3459543T3 (da) | 2023-02-13 |
| CA3024286A1 (en) | 2017-11-23 |
| WO2017200318A1 (ko) | 2017-11-23 |
| MX2018014080A (es) | 2019-04-04 |
| US10849882B2 (en) | 2020-12-01 |
| JP7071287B2 (ja) | 2022-05-18 |
| RU2753525C2 (ru) | 2021-08-17 |
| CN109475529B (zh) | 2022-02-22 |
| RU2018144785A3 (enExample) | 2020-08-11 |
| AU2017265839B2 (en) | 2022-10-27 |
| AU2017265839A1 (en) | 2018-12-13 |
| KR20170131242A (ko) | 2017-11-29 |
| EP3459543A1 (en) | 2019-03-27 |
| JP2019516707A (ja) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| MX394245B (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| BR112015026840A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia | |
| JOP20190053A1 (ar) | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط | |
| WO2015126930A3 (en) | Booster drug therapy for mycobacterium infections | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |